SK11882002A3 - Použitie prírodných zlúčenín s antiangiogénnou aktivitou - Google Patents
Použitie prírodných zlúčenín s antiangiogénnou aktivitou Download PDFInfo
- Publication number
- SK11882002A3 SK11882002A3 SK1188-2002A SK11882002A SK11882002A3 SK 11882002 A3 SK11882002 A3 SK 11882002A3 SK 11882002 A SK11882002 A SK 11882002A SK 11882002 A3 SK11882002 A3 SK 11882002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- chrysanthone
- compounds
- treatment
- activity
- use according
- Prior art date
Links
- USMNOWBWPHYOEA-UHFFFAOYSA-N 3‐isothujone Chemical class CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 230000001772 anti-angiogenic effect Effects 0.000 title claims description 9
- 229930185660 Chrysanthone Natural products 0.000 claims abstract description 26
- 229930135083 Pyrenoline A+ Natural products 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- VJCDPIZSSYQRCW-OCCSQVGLSA-N (6s,7r)-6,10-dihydroxy-7-methoxy-3-methyl-1,6,7,8-tetrahydrobenzo[g]isochromen-9-one Chemical compound C1OC(C)=CC2=C1C(O)=C1C(=O)C[C@@H](OC)[C@@H](O)C1=C2 VJCDPIZSSYQRCW-OCCSQVGLSA-N 0.000 claims abstract description 11
- VJCDPIZSSYQRCW-UHFFFAOYSA-N Chrysanthone B Natural products C1OC(C)=CC2=C1C(O)=C1C(=O)CC(OC)C(O)C1=C2 VJCDPIZSSYQRCW-UHFFFAOYSA-N 0.000 claims abstract description 11
- QLNCKOAYSCTIMZ-JZHZUCMVSA-N (6s,7r)-3,6,10-trihydroxy-7-methoxy-3-methyl-4,6,7,8-tetrahydro-1h-benzo[g]isochromen-9-one Chemical compound C1OC(C)(O)CC2=C1C(O)=C1C(=O)C[C@@H](OC)[C@@H](O)C1=C2 QLNCKOAYSCTIMZ-JZHZUCMVSA-N 0.000 claims abstract description 10
- QLNCKOAYSCTIMZ-UHFFFAOYSA-N Chrysanthone C Natural products C1OC(C)(O)CC2=C1C(O)=C1C(=O)CC(OC)C(O)C1=C2 QLNCKOAYSCTIMZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 230000002917 arthritic effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 230000033115 angiogenesis Effects 0.000 abstract description 15
- 230000002159 abnormal effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000035605 chemotaxis Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
- 229960005314 suramin Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241001108995 Messa Species 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 102000007614 Thrombospondin 1 Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000128A IT1317000B1 (it) | 2000-03-13 | 2000-03-13 | Uso di composti di origine naturale ad attivita' antiangiogenica. |
| PCT/IT2001/000120 WO2001068071A2 (en) | 2000-03-13 | 2001-03-12 | Use of natural chrysanthone compounds having antiangiogenic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK11882002A3 true SK11882002A3 (sk) | 2003-02-04 |
Family
ID=11454525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1188-2002A SK11882002A3 (sk) | 2000-03-13 | 2001-03-12 | Použitie prírodných zlúčenín s antiangiogénnou aktivitou |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6887883B2 (de) |
| EP (1) | EP1274408B1 (de) |
| JP (1) | JP2004500395A (de) |
| KR (1) | KR20020081420A (de) |
| AT (1) | ATE285230T1 (de) |
| AU (1) | AU2001244537A1 (de) |
| CA (1) | CA2401267A1 (de) |
| CZ (1) | CZ20022761A3 (de) |
| DE (1) | DE60107942T2 (de) |
| ES (1) | ES2234827T3 (de) |
| HU (1) | HUP0302472A2 (de) |
| IT (1) | IT1317000B1 (de) |
| MX (1) | MXPA02008952A (de) |
| PL (1) | PL356931A1 (de) |
| PT (1) | PT1274408E (de) |
| SK (1) | SK11882002A3 (de) |
| WO (1) | WO2001068071A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101094157B1 (ko) | 2011-04-04 | 2011-12-14 | 임세규 | 식물생약재를 이용한 당뇨개선용 건강보조식품 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843755A (en) * | 1996-05-20 | 1998-12-01 | Ajinomoto Co., Inc. | Group of antitumor compounds and method for producing the same |
| AU751283B2 (en) * | 1998-07-14 | 2002-08-08 | Bristol-Myers Squibb Company | Lysine binding fragments of angiostatin |
-
2000
- 2000-03-13 IT IT2000RM000128A patent/IT1317000B1/it active
-
2001
- 2001-03-12 CZ CZ20022761A patent/CZ20022761A3/cs unknown
- 2001-03-12 US US10/220,184 patent/US6887883B2/en not_active Expired - Fee Related
- 2001-03-12 KR KR1020027011811A patent/KR20020081420A/ko not_active Application Discontinuation
- 2001-03-12 JP JP2001566635A patent/JP2004500395A/ja active Pending
- 2001-03-12 SK SK1188-2002A patent/SK11882002A3/sk unknown
- 2001-03-12 PL PL01356931A patent/PL356931A1/xx not_active Application Discontinuation
- 2001-03-12 DE DE60107942T patent/DE60107942T2/de not_active Expired - Fee Related
- 2001-03-12 CA CA002401267A patent/CA2401267A1/en not_active Abandoned
- 2001-03-12 ES ES01917464T patent/ES2234827T3/es not_active Expired - Lifetime
- 2001-03-12 MX MXPA02008952A patent/MXPA02008952A/es active IP Right Grant
- 2001-03-12 AU AU2001244537A patent/AU2001244537A1/en not_active Abandoned
- 2001-03-12 WO PCT/IT2001/000120 patent/WO2001068071A2/en active IP Right Grant
- 2001-03-12 EP EP01917464A patent/EP1274408B1/de not_active Expired - Lifetime
- 2001-03-12 AT AT01917464T patent/ATE285230T1/de not_active IP Right Cessation
- 2001-03-12 HU HU0302472A patent/HUP0302472A2/hu unknown
- 2001-03-12 PT PT01917464T patent/PT1274408E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA02008952A (es) | 2003-04-25 |
| ATE285230T1 (de) | 2005-01-15 |
| JP2004500395A (ja) | 2004-01-08 |
| ITRM20000128A0 (it) | 2000-03-13 |
| DE60107942T2 (de) | 2005-12-08 |
| CA2401267A1 (en) | 2001-09-20 |
| AU2001244537A1 (en) | 2001-09-24 |
| WO2001068071A3 (en) | 2002-06-06 |
| US6887883B2 (en) | 2005-05-03 |
| EP1274408A2 (de) | 2003-01-15 |
| PL356931A1 (en) | 2004-07-12 |
| DE60107942D1 (de) | 2005-01-27 |
| WO2001068071A2 (en) | 2001-09-20 |
| EP1274408B1 (de) | 2004-12-22 |
| HUP0302472A2 (hu) | 2003-12-29 |
| ITRM20000128A1 (it) | 2001-09-13 |
| CZ20022761A3 (cs) | 2003-03-12 |
| US20030149068A1 (en) | 2003-08-07 |
| IT1317000B1 (it) | 2003-05-26 |
| PT1274408E (pt) | 2005-03-31 |
| ES2234827T3 (es) | 2005-07-01 |
| KR20020081420A (ko) | 2002-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ji et al. | Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells | |
| Lee et al. | Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models | |
| Wilcox et al. | Perivascular responses after angioplasty which may contribute to postangioplasty restenosis: a role for circulating myofibroblast precursors? | |
| Carlson et al. | Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of urokinase plasminogen activator | |
| AU2004263009B2 (en) | Pharmaceutical compositions and methods for accelerating wound healing | |
| Iwai‐Kanai et al. | Basic fibroblast growth factor protects cardiac myocytes from iNOS‐mediated apoptosis | |
| Hemmer et al. | Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels | |
| Huang et al. | Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510 | |
| US20120128697A1 (en) | NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis | |
| US20180344680A1 (en) | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers | |
| JPH08510451A (ja) | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 | |
| Cheng et al. | Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway | |
| Ling et al. | The effect of 2, 3, 4′, 5-tetrahydroxystilbene-2-0-β-d glucoside on neointima formation in a rat artery balloon injury model and its possible mechanisms | |
| Ferreira et al. | The search for biomarkers and treatments in Chagas disease: insights from TGF-beta studies and immunogenetics | |
| US20100204254A1 (en) | Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin | |
| Qu et al. | Vitamin C Treatment Rescues Prelamin A‐Induced Premature Senescence of Subchondral Bone Mesenchymal Stem Cells | |
| Iurlaro et al. | Beta interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid | |
| Inoue et al. | Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double‐injury model | |
| Bar-Joseph et al. | Pigment epithelium–derived factor exerts antioxidative effects in granulosa cells | |
| Parfyonova et al. | Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury | |
| Himelstein et al. | Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts | |
| CN108434139A (zh) | 缺氧诱导因子脯氨酰羟化酶活性抑制剂在制备防治急性肾损伤药物中的应用 | |
| SK11882002A3 (sk) | Použitie prírodných zlúčenín s antiangiogénnou aktivitou | |
| Yi et al. | Anti-angiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative | |
| Lapi et al. | Effects of bone marrow mesenchymal stem cells (BM-MSCs) on rat pial microvascular remodeling after transient middle cerebral artery occlusion |